Held by 2 specialist biotech funds
**Signal Note: Eventide Values-Based Allocation Shift to SHOP** This $2.4M position initiation is notable given Eventide's biotech-focused mandate, suggesting conviction that SHOP's e-commerce infrastructure—particularly in health/wellness verticals—aligns with their values thesis or represents portfolio diversification into adjacent healthtech. The timing may reflect confidence in SHOP's pharmacy/telehealth integrations or direct-to-consumer health brand enablement, which could benefit from biotech company commercialization strategies post-approval.